Gå til hovedindhold

NIS2 and SME Cybersecurity in Life Sciences

Mandatory cybersecurity risk management frameworks establish uniform defensive baselines across critical European infrastructure and healthcare networks. Small and medium enterprises in the life sciences sector face significant governance and operational constraints when implementing cross-border compliance mechanisms. Assessing regulatory alignment against specialized operational realities identifies essential pathways for resilient digital health ecosystems.

Målet med arbejdet

To evaluate how NIS2 compliance mandates interact with operational cybersecurity capabilities in life sciences SMEs.

Metodologi

Desk-based comparative analysis of EU statutory frameworks, maturity models, and sector-specific policy reports.

Videnskabelig nyhedsværdi

Isolates the operational friction between NIS2 supply chain obligations and resource-constrained biomedical SMEs.

Dokument Forhåndsvisning

Dette er en kort forhåndsvisning. Den fulde version indeholder udvidet tekst til alle sektioner, en konklusion og en formateret bibliografi.

Research Article

Degree:
NIS2 and SME Cybersecurity in Life Sciences

Author:

Group

First M. Last

Advisor:

Dr. First Last

City, 2026

Contents

Abstract
Introduction
2. Regulatory Scope of NIS2 and Governance Mandates
3. Methodological Framework for Compliance Assessment
4. Life Sciences Vulnerability Profile and Digital Health Assets
5. Supply Chain Cybersecurity and Third-Party Dependencies
7. Discussion: Policy Gaps and Strategic Adaptation
Conclusion
Bibliography

Introduction

The integration of networked operational technologies in European healthcare infrastructure elevates exposure to complex digital disruption across critical sub-sectors [6]. Regulatory adaptation under the Network and Information Systems Directive imposes standardized baseline safeguards across digital service entities and essential operators [4]. Small and medium-sized biotechnology and pharmaceutical developers face heightened exposure during cross-border regulatory harmonization.

Modern biomedical supply chains increasingly rely on distributed interconnected environments that distribute vulnerability across external commercial partners [3]. Traditional security governance within small entities struggles to match the comprehensive risk-management obligations defined under Article 21 requirements [1]. This institutional disparity creates substantial operational frictions between statutory compliance mandates and operational technical execution.

Systematic investigation of regulatory expectations reveals structural gaps between legislative intent and small-enterprise defensive maturity [2]. This investigation evaluates the alignment of risk management protocols with practical organizational capabilities across the biomedical ecosystem. Documenting these structural intersections clarifies how standardized governance structures influence resilience without exhausting specialized organizational resources.

7. Discussion: Policy Gaps and Strategic Adaptation

The implementation of the NIS2 Directive across European life sciences ecosystems highlights a persistent tension between high-level regulatory mandates and the operational capacities of small and medium-sized enterprises. Although the directive mandates stringent risk-management procedures to secure critical health infrastructure, specialized healthcare providers, and essential digital assets, compliance frameworks often presume organizational maturity and dedicated resources that smaller entities struggle to maintain independently. The adoption of structured assessment models and dynamic knowledge representations, such as ontologies designed to evaluate compliance with Article 21 risk-management obligations, provides a crucial mechanism for systematically identifying defensive gaps and institutional readiness (Jenni0608, 2024). Nevertheless, formal adherence to risk management taxonomies does not entirely resolve the vulnerabilities embedded within complex third-party dependencies. Critical infrastructure networks increasingly rely on collaborative supply chains and interconnected technological ecosystems, where statutory governance provisions frequently build upon limited understandings of practical supply chain security intricacies and distributed partner risks ("The Regulation of Supply Chain Cybersecurity", 2024). Consequently, regulatory alignment alone cannot guarantee operational resilience unless life sciences enterprises integrate continuous technical self-evaluation with proactive supply chain oversight. Addressing these structural policy gaps demands harmonized guidance that standardizes incident reporting, enhances technical expertise, and fosters collaborative threat communication among regulatory authorities, software vendors, and biotechnology actors. Strategic adaptation must therefore transcend superficial bureaucratic compliance, enabling resource-constrained enterprises to operationalize baseline cybersecurity controls effectively across modern digital health networks.

References

  1. Jenni0608/NIS2Assessment: NIS2 Regulatory Assessment Tool
    Jenni, jenniparry
    DOI-link
  2. The Impact of the NIS2 Directive on the Cybersecurity of Finland's Transportation Sector
    Jyri Rajamäki, Tiina Kyrö
    DOI-link
  3. The Regulation of Supply Chain Cybersecurity in the NIS2 Directive in the Context of the Internet of Things
    Mattis anon
    DOI-link
  4. A NIS Directive compliant Cybersecurity Maturity Assessment Framework
    George Drivas, Argyro Chatzopoulou, Leandros Maglaras et al.
  5. Cybersecurity in the EU: How the Nis2-Directive Stacks Up Against its Predecessor
    Niels Vandezande
  6. Cybersecurity of critical infrastructure in europe: the NIS2 directive in focus
    Fabian Teichmann

Tilføj en litteraturliste til opgaven

Verificerede kilderFormateringsstandarderHøj originalitetPro-modeller
Launch Offer -25%

Artikel

APA 7 (Danish)

6 €8 €
  • 8–20 sider.
  • Høj originalitet
  • Eksport til Word
  • Korrekt formatering
  • Offentlig forhåndsvisning
    En forhåndsvisning af en anden forfatter kan ikke gøres privat. Dit arbejde vil være privat og helt unikt.
  • Litteraturliste (10+, APA 7)
    +2 €
  • Tilføj alternative kilder (Nyheder, .gov, .edu)

Artikel

APA 7 (Danish)